Skip to main content

Table 3 Characteristics of patients treated with nivolumab in responder and non-responder groups

From: Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study

Variables Responder (n = 21) Non-responder (n = 37) p
No. (%) No. (%)
Sex
 Male 18 (86%) 27 (73%) 0.338
 Female 3 (14%) 10 (27%)
Age (years) (Median, Range) 66 (53–76) 66 (38–82) 0.581
ECOG performance status
 0 6 (29%) 2 (5%) 0.021
  ≥ 1 15 (71%) 35 (95%)
Disease status
 Metastatic 16 (76%) 27 (73%) 1
 Relapsed 5 (24%) 10 (27%)
Primary site
 Gastric 17 (81%) 32 (87%) 0.71
 Esophagogastric junction 4 (19%) 5 (14%)
Histological type
 Intestinal type 12 (57%) 22 (60%) 1
 Diffuse type 9 (43%) 15 (40%)
HER-2 status
 Positive 2 (10%) 11 (30%) 0.106
Site of metastases
 Lymph nodes 13 (62%) 28 (76%) 0.369
 Hematogenous 9 (43%) 24 (65%) 0.167
 Peritoneum 12 (57%) 15 (41%) 0.278
Organs with metastasis
 1 11 (52%) 6 (16%) 0.006
  ≥ 2 10 (48%) 31 (84%)
Previous treatment regimens
 2 14 (67%) 21 (57%) 0.704
 3 5 (24%) 13 (35%)
  ≥ 4 2 (9%) 3 (8%)
Previous therapies
 Pyrimidine analogs 20 (95%) 36 (97%) 1
 Platinum 18 (86%) 32 (87%) 1
 Taxane 20 (95%) 35 (95%) 1
 Ramucirumab 16 (76%) 32 (87%) 0.471
 Trastuzumab 2 (10%) 9 (24%) 0.296
 Irinotecan 5 (24%) 11 (30%) 0.764
Treatment period before nivolumab (months) 17.3 (8.1–37.1) 14.6 (4.9–64.6) 0.225
Immune-related adverse events
 Positive 7 (33%) 3 (8%) 0.027